Pharmacogenetics of the response to statins

Current Cardiovascular Risk Reports

Volumn 3, Issue 6, 2009, Pages 434-440

  Voora, Deepak ^b   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959467949     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-009-0064-1     Document Type: Review

References (43)

1. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005, 366: 1267-1278.
2. Ho PM, Magid DJ, Shetterly SM, et al.: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155: 772-779.
3. Jacobson TA: Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83: 687-700.
4. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110: 227-239.
5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497.
6. Yan AT, Yan RT, Tan M, et al.: Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006, 119: 676-683.
7. Davidson MH, Maki KC, Pearson TA, et al.: Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005, 96: 556-563.
8. Waters DD, Brotons C, Chiang CW, et al.: Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120: 28-34.
9. Schmitz G, Drobnik W: Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med 2003, 41: 581-589.
10. Simon JA, Lin F, Hulley SB, et al.: Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 2006, 97: 843-850.
11. Shear CL, Franklin FA, Stinnett S, et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992, 85: 1293-1303.
12. Thompson JF, Man M, Johnson KJ, et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005, 5: 352-358.
13. Chasman DI, Posada D, Subrahmanyan L, et al.: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291: 2821-2827.
14. Voora D, Shah SH, Reed CR, et al.: Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008, 1: 100-106.
15. Thompson JF, Hyde CL, Wood LS, et al.: Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet 2009, 2: 173-181.
16. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M: ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008, 84: 457-461.
17. Fiegenbaum M, da Silveira FR, van der Sand CR, et al.: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment [abstract]. Clin Pharmacol Ther 2005, 78: 551-558.
18. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004, 93: 1046-1050.
19. Krauss RM, Mangravite LM, Smith JD, et al.: Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008, 117: 1537-1544.
20. Medina MW, Gao F, Ruan W, et al.: Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme a reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008, 118: 355-362.
21. Cohen J, Pertsemlidis A, Kotowski IK, et al.: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37: 161-165.
22. Kathiresan S, Melander O, Anevski D, et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008, 358: 1240-1249.
23. Iakoubova OA, Tong CH, Rowland CM, et al.: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51: 435-443.
24. Iakoubova OA, Sabatine MS, Rowland CM, et al.: Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE ITTIMI 22 study. J Am Coll Cardiol 2008, 51: 449-455.
25. Nichols GA, Koro CE: Does statin therapy initiation increase the risk for myopathy? an observational study of 32, 225 diabetic and nondiabetic patients. Clin Ther 2007, 29: 1761-1770.
26. Bays H: Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006, 97: 6C-26C.
27. Hermann M, Bogsrud MP, Molden E, et al.: Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006, 79: 532-539.
28. Voora D, Shah SH, Spasojevic I, et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009 (in press).
29. Link E, Parish S, Armitage J, et al.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359: 789-799.
30. Gotto AM: Statins, cardiovascular disease, and drug safety. Am J Cardiol 2006, 97: S3-S5.
31. Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97: S69-S76.
32. Kameyama Y, Yamashita K, Kobayashi K, et al.: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genom 2005, 15: 513-522.
33. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genom 2006, 16: 873-879.
34. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007, 82: 726-733.
35. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin [abstract]. Clin Pharmacol Ther 2006, 80: 356-366.
36. Cziraky MJ, Willey VJ, McKenney JM, et al.: Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006, 97: S61-S68.
37. Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002, 105: 2341-2346.
38. Skottheim IB, Gedde-Dahl A, Hejazifar S, et al.: Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008.
39. Frudakis TN, Thomas MJ, Ginjupalli SN, et al.: CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genom 2007, 17: 695-707.
40. Zuccaro P, Mombelli G, Calabresi L, et al.: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007, 55: 310-317.
41. Ruano G, Thompson PD, Windemuth A, et al.: Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007, 36: 329-335.
42. Vladutiu GD, Simmons Z, Isackson PJ, et al.: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006, 34: 153-162.
43. Ho PM, Bryson CL, Rumsfeld JS: Medication adherence: its importance in cardiovascular outcomes. Circulation 2009, 119: 3028-3035.